The Scientist

» drug development

Most Recent

image: Q&A: From FDA to Industry

Q&A: From FDA to Industry

By | September 27, 2016

Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.

0 Comments

image: Allergan’s Buying Spree Rolls On

Allergan’s Buying Spree Rolls On

By | September 21, 2016

The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.

0 Comments

image: Feds Demand More Clinical Trial Reporting

Feds Demand More Clinical Trial Reporting

By | September 19, 2016

Expanded US Health and Human Services rules will require the results of more human studies to be made public.

1 Comment

image: Allergan Set to Buy Vitae

Allergan Set to Buy Vitae

By | September 16, 2016

The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.

0 Comments

image: The Challenges of Rare-Disease Research

The Challenges of Rare-Disease Research

By | September 1, 2016

With few resources and hesitant investors, basic scientists must rely on clinicians, patient advocates, and their own keen eye for biological connections.

0 Comments

image: Pfizer to Buy Medivation for $14 Billion

Pfizer to Buy Medivation for $14 Billion

By | August 22, 2016

The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.

0 Comments

image: The Growth of Iowa Biotech

The Growth of Iowa Biotech

By | August 1, 2016

The state’s industry draws inspiration from medicine as well as agriculture.

1 Comment

image: Mystery Mechanisms

Mystery Mechanisms

By | July 29, 2016

Scientists still don’t know exactly how some commonly used drugs work. Here’s a look at three such compounds.

0 Comments

The change should allow patients with fatal illnesses easier access to experimental drugs, but gaining permission from drug companies remains the biggest challenge.

0 Comments

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

1 Comment

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech